logo
Inmate training program shelved while prison construction talks continue

Inmate training program shelved while prison construction talks continue

Yahoo10-06-2025
Participants in a welding program for minimum security inmates are pictured at Southeast Technical College in Sioux Falls on Oct. 7, 2024. (John Hult/South Dakota Searchlight)
The South Dakota Department of Corrections will not offer a promised diesel mechanic training program in a space once occupied by a privately run metal shop that paid inmates market wages.
Last August, the DOC and Southeast Technical College got approval from the state Board of Technical Education to expand the college's diesel program into the maximum security Jameson Annex in Sioux Falls.
Training inmates to fix diesel engines would 'create opportunities within our community to meet the workforce needs of trades careers,' according to the school and the department's application to the board.
The application anticipated an August 2025 opening.
Private employers say they were pushed out of state prisons
Corrections spokesman Michael Winder told South Dakota Searchlight last week, however, that the school was unable to secure funding to purchase the equipment needed to operate the program inside the Sioux Falls prison.
Jennifer Lambley of Southeast Tech said ongoing debate about the potential construction of a new prison was partially to blame for the decision to freeze talks on the diesel program. The school had been in discussions with the nonprofit Vera Institute of Justice on potential funding.
'We believe it's important to pause and more deeply consider how this initiative fits into South Dakota's broader plans for addressing long-term prison infrastructure and programming needs,' Lambley said.
Winder and Lambley both said that the school and DOC still aim to expand programming for inmates eventually.
'We remain fully committed to providing high-quality, workforce-relevant education to individuals in custody,' Lambley said.
The diesel engine program was set to fill the now-empty space occupied for more than 20 years by Metal Craft Industries, a company that says it was pushed out of the prison system by administrators. Corrections Secretary Kellie Wasko said the company left voluntarily to avoid adhering to newer, stricter security protocols.
The owner of another private business that had employed female inmates in Pierre, Badlands Quilting, also accused the state of pushing it out the door last year.
The shuttered metal shop's status came up briefly during a meeting of the Project Prison Reset group last week in Pierre. Consultants with the firm Arrington Watkins said the shop was empty when they toured the Jameson Annex of the South Dakota State Penitentiary in Sioux Falls a few months ago.
The work group is focused on building options that might relieve inmate overcrowding, but its members have also focused on repeat offense rates, reentry programming, job training and post-incarceration placement.
Many task force members and members of the public who've appeared at the meetings have argued that the state needs to do more to improve the chances for inmates who return to their communities after serving a sentence if it ever hopes to address long-term growth in prison populations.
Last week, the group voted to cap spending on a new prison at $600 million. That's less than the consultants suggested would be necessary to build one big enough to meet current needs and address future growth projections.
Sen. Jamie Smith, D-Sioux Falls, lamented that the cap could hamstring efforts to design a facility capable of training current inmates to become rehabilitated, contributing members of their communities.
Smith didn't mention Metal Craft Industries last week, but the controversy surrounding its departure sparked a host of questions from lawmakers last year on the role of work programs within the DOC.
Inmates at Mike Durfee State Prison work for the Governors Home program, which builds houses, duplexes and day cares for people under certain incomes and communities that meet certain guidelines.
The state also operates a handful of shops under the banner of Pheasantland Industries, including an upholstery shop that outfits prison cells and a sign shop that prints license plates and road signs.
Metal Craft and Badlands Quilting paid inmates market wages. Some inmates paid off their restitution and child support with their Metal Craft paychecks, and employees of both private businesses paid room and board to the state. Most prison jobs, by contrast, pay about 50 cents an hour.
During previous Project Prison Reset meetings, inmates and their family members said extended lockdowns across the system have served as an impediment to job training programs, kept shops from running full-time and otherwise hindered inmates' opportunities to better themselves.
'There's classrooms in here that sit empty half the time,' inmate Samuel Lint told the group through a cell phone in early April.
Prison task force rejects original Lincoln County site, tightens budget for new facility
Programs that train inmates outside prison walls have had success, though.
Twelve minimum custody inmates graduated with welding certificates from Southeast Tech last fall, adding to the 57 who'd completed the training since 2022. The welding certificate program is funded with help from the state Department of Labor.
Past cohorts have had an average graduation rate of more than 80% and a similar job placement rate, an announcement on the fall graduation said. The money from the Labor Department covered the cost of books and equipment for inmate students.
Dawn Dovre, spokesperson for the department, told South Dakota Searchlight in an email that part of the funding is from the U.S. Department of Labor.
'As always, if there are changes to these programs or budgets nationally, adjustments to service delivery will be made,' Dovre said.
The Department of Corrections also offers Career and Technical Education courses in precision machining for male offenders at Mike Durfee State Prison in Springfield through Lake Area Technical College.
That program didn't field a cohort in the spring, according to Tiffany Sanderson, Lake Area's president, but not for a lack of funding.
The former instructor left last fall, and Sanderson said it's been hard to fill that position.
Offenders at the Rapid City Minimum Center can enroll in a plumbing course at Western Dakota Technical College. That school's spokesperson told South Dakota Searchlight that five inmates graduated from the course this spring.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Healthpeak Properties (DOC) Drops 6.7% on Steep Q2 Earnings Dive
Healthpeak Properties (DOC) Drops 6.7% on Steep Q2 Earnings Dive

Yahoo

time2 days ago

  • Yahoo

Healthpeak Properties (DOC) Drops 6.7% on Steep Q2 Earnings Dive

We recently published . Healthpeak Properties, Inc. (NYSE:DOC) is one of the worst-performing stocks on Friday. Healthpeak Properties declined by 6.73 percent on Friday to close at $17.6 apiece following a steep drop in its earnings performance in the second quarter of the year. In its earnings release, Healthpeak Properties, Inc. (NYSE:DOC) said net income attributable to shareholders during the period fell by 78 percent to $31.5 million from $145.8 million in the same period last year, dragging its first half figures by 51 percent to $73.9 million from $152 million year-on-year. Revenues for the quarter ended flat at $694 million, while revenues for the first half dropped by 7 percent to $1.397 billion from $1.3 billion year-on-year. Following the performance, Healthpeak Properties, Inc. (NYSE:DOC) lowered its growth guidance for full-year 2025, with diluted earnings per common share now pegged at 25-31 cents from 30-36 cents previously. On July 31, shareholders as of July 18 will receive dividends worth $0.10167 for each common share held. Another dividend with the same amount will be paid on August 29, for shareholders as of the August 18 record. While we acknowledge the potential of DOC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y
Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y

Yahoo

time2 days ago

  • Yahoo

Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y

Healthpeak Properties, Inc. DOC reported second-quarter 2025 funds from operations ('FFO') as adjusted per share of 46 cents, meeting the Zacks Consensus Estimate. The metric was 45 cents per share in the prior-year quarter. Results reflect lower-than-expected revenues. Growth in total merger-combined same-store cash (adjusted) net operating income ('NOI') was witnessed across the portfolio. However, higher interest expenses affected the results to some extent. This healthcare real estate investment trust ('REIT') generated revenues of $694.3 million, marginally missing the Zacks Consensus Estimate of $694.6 million. The figure also slightly declined year over year. Behind DOC's Earnings Headlines In the second quarter, Healthpeak reported 3.5% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI. DOC witnessed 3.9% and 1.5% year-over-year growth in the total merger-combined same-store cash (adjusted) NOI for its outpatient medical and lab segments, respectively. The CCRC segment reported growth of 8.6%. During the reported quarter, Healthpeak executed new and renewal leases totaling 503,000 square feet, with retention at 87% and positive 6% cash-releasing spreads on renewals in the lab portfolio. For the outpatient medical portfolio, new and renewal leases aggregated 1 million square feet, with retention at 85% and positive 6% cash-releasing spreads on renewals. However, interest expenses marginally jumped year over year to $75.1 million. DOC's Balance Sheet Healthpeak exited the second quarter with cash and cash equivalents of $89.4 million, up from $70.6 million as of March 31, 2025. Its net debt to adjusted EBITDAre was 5.2X as of June 30, 2025. In June 2025, Healthpeak repaid $452 million as 4% senior notes at maturity. DOC's 2025 Outlook Healthpeak has reaffirmed its previous guidance. The company expects its 2025 FFO as adjusted per share to be between $1.81 and $1.87. The Zacks Consensus Estimate is presently pegged at $1.85 per share, which is within expectations. The total merger-combined same-store cash (adjusted) NOI growth is estimated to be in the range of 3-4%. Healthpeak currently carries a Zacks Rank #4 (Sell). Healthpeak Properties, Inc. Price, Consensus and EPS Surprise Healthpeak Properties, Inc. price-consensus-eps-surprise-chart | Healthpeak Properties, Inc. Quote Upcoming Earnings Releases We now look forward to the earnings releases of other healthcare REITs, such as Welltower, Inc. WELL and Ventas, Inc. VTR, slated to report on July 28 and July 30, respectively. The Zacks Consensus Estimate for Welltower's second-quarter 2025 FFO per share is pegged at $1.22, implying a 16.2% year-over-year increase. WELL currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Ventas' second-quarter 2025 FFO per share is pinned at 85 cents, indicating a 6.3% rise year over year. VTR currently has a Zacks Rank #3. Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ventas, Inc. (VTR) : Free Stock Analysis Report Healthpeak Properties, Inc. (DOC) : Free Stock Analysis Report Welltower Inc. (WELL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity

Business Upturn

time5 days ago

  • Business Upturn

Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity

New York, USA, July 22, 2025 (GLOBE NEWSWIRE) — Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launch of emerging therapies such as Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), and others, heightened UV exposure, advancements in diagnostic techniques, and lifestyle changes. DelveInsight's Melanoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging melanoma drugs, market share of individual therapies, and current and forecasted Melanoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Melanoma Market Report According to DelveInsight's analysis, the total melanoma market size is expected to grow positively by 2034. The United States accounts for the largest market size of melanoma, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. In 2024, the total number of incident cases of melanoma was approximately 105K in the US. The trend indicates that melanoma occurs more frequently in males than in females, and around 20% of cases eventually progress to advanced stages (stage III/IV), involving unresectable or distant metastatic disease. in the US. The trend indicates that melanoma occurs more frequently in males than in females, and around of cases eventually progress to advanced stages (stage III/IV), involving unresectable or distant metastatic disease. Prominent companies, including Istari Oncology, Philogen, Georgiamune, Diakonos Oncology, Immatics Biotechnologies, Replimune, BMS, Ascentage Pharma, Erasca, Krystal Biotech, IDEAYA Biosciences, Novartis, HUYA Bioscience, Regeneron Pharmaceuticals, and others, are actively working on innovative melanoma drugs. and others, are actively working on innovative melanoma drugs. Some of the key melanoma therapies in the pipeline include Lerapolturev, Nidlegy, GIM-531, DOC-1021, IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, APG-115, Naporafenib (ERAS-254), KB707, Darovasertib (IDE196), HBI-8000, Fianlimab , and others. These novel melanoma therapies are anticipated to enter the melanoma market in the forecast period and are expected to change the market. , and others. These novel melanoma therapies are anticipated to enter the melanoma market in the forecast period and are expected to change the market. In May 2025, Immatics announced the presentation of expanded data from the ongoing Phase Ib clinical trial evaluating IMA203 in heavily pretreated patients with metastatic melanoma announced the presentation of expanded data from the ongoing Phase Ib clinical trial evaluating IMA203 in heavily pretreated patients with metastatic melanoma In April 2025, IDEAYA Biosciences announced a successful FDA Type D meeting on the Phase III registrational trial design that would assess the safety and efficacy of darovasertib for potential regulatory approval as neoadjuvant therapy for primary uveal melanoma. Discover which melanoma medications are expected to grab the market share @ Melanoma Market Report Melanoma Overview Melanoma is a type of skin cancer that originates in melanocytes, the pigment-producing cells responsible for giving skin its color. While it is less common than other skin cancers, melanoma is significantly more aggressive and has a higher risk of spreading to other parts of the body if not detected early. It can occur anywhere on the body but is most frequently found on areas exposed to the sun, such as the back, legs, arms, and face. The primary cause of melanoma is ultraviolet radiation from sunlight or artificial sources like tanning beds, which can damage the DNA in skin cells. Individuals with fair skin, a history of sunburns, a large number of moles, or a family history of melanoma are at higher risk. Genetic mutations, such as in the BRAF gene, also play a significant role in the development of melanoma in certain cases. Symptoms of melanoma often begin with changes in the appearance of a mole or pigmented area. Warning signs include asymmetry, irregular borders, color variation, a diameter larger than 6 mm, and evolving shape or size, summarized by the ABCDE rule. Itching, bleeding, or the appearance of a new mole can also be concerning signs. Diagnosis typically involves a thorough skin examination followed by a biopsy of any suspicious lesion. If melanoma is confirmed, further tests such as sentinel lymph node biopsy, imaging scans (CT, MRI, or PET), and blood work may be conducted to determine the stage and whether the cancer has spread. Early diagnosis is critical, as it significantly improves the prognosis and expands treatment options. Melanoma Epidemiology Segmentation The melanoma epidemiology section provides insights into the historical and current melanoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The melanoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Incident Cases of Melanoma Stage-specific Incident Cases of Melanoma Mutation-specific Incident Cases of Melanoma Line-wise Treated Cases of Melanoma Download the report to understand which factors are driving melanoma epidemiology trends @ Melanoma Treatment Algorithm Melanoma Treatment Market There remains a substantial unmet need for effective treatment options in melanoma patients who are resistant to, unsuitable for, or unresponsive to standard therapies like checkpoint inhibitors or BRAF/MEK-targeted treatments. The FDA has approved several therapies for melanoma, including AMTAGVI (lifileucel, Iovance Biotherapeutics), OPDUALAG (nivolumab + relatlimab, Bristol Myers Squibb), KEYTRUDA (pembrolizumab, Merck), OPDIVO (nivolumab, BMS), KIMMTRAK (tebentafusp-tebn, Immunocore), YERVOY (ipilimumab, BMS), TECENTRIQ (atezolizumab, Roche), among others. AMTAGVI, from Iovance Biotherapeutics, became the first FDA-approved, personalized, one-time T cell therapy in February 2024. It is intended for adults with unresectable or metastatic melanoma who have previously been treated with PD-1 inhibitors, and for those with BRAF V600 mutations, after BRAF inhibitor ± MEK inhibitor therapy. That same year, Iovance submitted a Marketing Authorization Application (MAA) for lifileucel to the EMA in June (validated in August) and to the UK's MHRA in October. In June 2025, Iovance announced that the final results from the Phase II C-144-01 trial of AMTAGVI in advanced melanoma patients were published in the Journal of Clinical Oncology and presented at the 2025 ASCO Annual Meeting. Bristol Myers Squibb's OPDUALAG combines nivolumab, a PD-1 inhibitor, with relatlimab, a LAG-3 inhibitor, and is indicated for the treatment of unresectable or metastatic melanoma. The FDA approved it in March 2022 for adults and children aged 12 and above. However, in February 2025, BMS reported that the Phase III RELATIVITY-098 trial did not achieve its primary endpoint of recurrence-free survival (RFS) in the adjuvant setting for completely resected stage III–IV melanoma, although the safety profile remained consistent with existing data on the combination. KEYTRUDA and OPDIVO both demonstrate strong efficacy in treating melanoma, though OPDIVO has gained greater commercial traction through effective combination regimens and broader clinical use. Despite metastatic melanoma often being incurable, the emergence of advanced treatments such as immune checkpoint inhibitors and targeted therapies has markedly improved survival and quality of life, signaling a significant evolution in the standard of care. Learn more about the melanoma treatment options @ Melanoma Treatment Guidelines Melanoma Emerging Drugs and Companies Some of the products in the pipeline include Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), RP1 (vusolimogene oderparepvec) plus nivolumab (Replimune and BMS), APG-115 (Ascentage Pharma), Naporafenib (ERAS-254) (Erasca), KB707 (Krystal Biotech), Darovasertib (IDE196) (IDEAYA Biosciences and Novartis), HBI-8000 (HUYA Bioscience and BMS), Fianlimab (Regeneron Pharmaceuticals), and others. IMA203 is a TCR T-cell therapy that targets the Preferentially Expressed Antigen in Melanoma (PRAME). It's designed to identify an intracellular PRAME-derived peptide displayed on the surface of cells by HLA-A*02:01, triggering a strong and specific anti-tumor immune response. Encouraging Phase Ib results, along with PRAME's high expression rate in melanoma (~90–95%), support IMA203's therapeutic promise. The therapy is currently under investigation in the SUPRAME Phase III trial (NCT06743126) for previously treated advanced or metastatic cutaneous melanoma, and its Phase Ib expansion now includes uveal melanoma. According to the company's 2024 Annual Report, interim analysis for IMA203 is expected in Q1 2026, with final Phase III results in Q4 2026. A Biologics License Application (BLA) submission is planned for Q1 2027, aiming for a market launch in Q3 2027. RP1 is a herpes simplex virus-based therapy modified with a fusogenic protein (GALV-GP R) and GM-CSF to enhance tumor cell destruction, increase immunogenic cell death, and promote a systemic anti-tumor immune response. The FDA has awarded Breakthrough Therapy Designation (BTD) for RP1 in combination with nivolumab for adults with advanced melanoma that has progressed after anti-PD1 treatment. In June 2025, Replimune shared updated results from the IGNYTE study (RP1 + nivolumab in anti-PD1-refractory melanoma) at the 2025 ASCO Annual Meeting. Darovasertib (IDE196) is a potent, selective PKC inhibitor in clinical development. PKC lies downstream of the GNAQ and GNA11 pathways. Darovasertib is currently in a Phase III trial for primary non-metastatic uveal melanoma, a Phase II/III (DAR-UM-2) study for HLA-A2-negative metastatic uveal melanoma (MUM), and other Phase II trials in ocular melanoma. The company expects results from the pivotal DAR-UM-2 trial in first-line HLA-A2-negative MUM by late 2025. In March 2025, the FDA granted BTD to darovasertib for neoadjuvant treatment of primary uveal melanoma patients recommended for enucleation. The anticipated launch of these emerging melanoma therapies are poised to transform the Melanoma market landscape in the coming years. As these cutting-edge melanoma therapies continue to mature and gain regulatory approval, they are expected to reshape the melanoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for melanoma, visit @ Melanoma Management Melanoma Market Dynamics The melanoma market dynamics are anticipated to change in the coming years. Drugs like OPDIVO and KEYTRUDA, particularly in combination with ipilimumab, have significantly improved overall survival and achieved durable response rates (~30–40%) in metastatic melanoma; however, the limited long-term efficacy in many patients highlights the urgent need for effective second-line therapies and continued innovation. With nearly 50% of melanoma patients harboring BRAF mutations, targeted therapy has become a viable option, while molecular profiling enables patient stratification even in refractory settings for clinical trials and off-label interventions. Moreover, targeting underrepresented melanoma subtypes such as uveal, mucosal, and acral presents opportunities for market expansion and accelerated regulatory pathways, given the high unmet need and paucity of existing therapies. Furthermore, many potential therapies are being investigated for the treatment of melanoma, and it is safe to predict that the treatment space will significantly impact the melanoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the melanoma market in the 7MM. However, several factors may impede the growth of the melanoma market. Moreover, melanoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the melanoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the melanoma market growth. Melanoma Report Metrics Details Study Period 2020–2034 Melanoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Melanoma Companies Istari Oncology, Philogen, Georgiamune, Diakonos Oncology, Immatics Biotechnologies, Replimune, BMS, Ascentage Pharma, Erasca, Krystal Biotech, IDEAYA Biosciences, Novartis, HUYA Bioscience, Regeneron Pharmaceuticals, and others Key Melanoma Therapies Lerapolturev, Nidlegy, GIM-531, DOC-1021, IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, APG-115, Naporafenib (ERAS-254), KB707, Darovasertib (IDE196), HBI-8000, Fianlimab, and others Scope of the Melanoma Market Report Melanoma Therapeutic Assessment: Melanoma current marketed and emerging therapies Melanoma current marketed and emerging therapies Melanoma Market Dynamics: Conjoint Analysis of Emerging Melanoma Drugs Conjoint Analysis of Emerging Melanoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Melanoma Market Access and Reimbursement Discover more about melanoma drugs in development @ Melanoma Clinical Trials Table of Contents 1. Melanoma Market Key Insights 2. Melanoma Market Report Introduction 3. Melanoma Market Overview at a Glance 4. Melanoma Market Executive Summary 5. Disease Background and Overview 6. Melanoma Treatment and Management 7. Melanoma Epidemiology and Patient Population 8. Patient Journey 9. Melanoma Marketed Drugs 10. Melanoma Emerging Drugs 11. Seven Major Melanoma Market Analysis 12. Melanoma Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis Related Reports Melanoma Pipeline Melanoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key melanoma companies, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, among others. Ocular Melanoma Market Ocular Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ocular melanoma companies, including Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline PLC, Amgen Inc., among others. Uveal Melanoma Market Uveal Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveal melanoma companies, including Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, among others. Metastatic Melanoma Market Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic melanoma companies, including Cancer Insight LLC, Elios Therapeutics LLC, Evaxion Biotech A/S, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, InxMed (Shanghai) Co. Ltd., Aivita Biomedical Inc., Hoffmann-La Roche, Idera Pharmaceuticals, Iovance Biotherapeutics Inc., Eisai Inc., Biocad, Myrexis Inc., Pain Therapeutics, Altor BioScience, among others. Refractory Metastatic Melanoma Market Refractory Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory metastatic melanoma companies, including BioNTech SE, Y-mAbs Therapeutics, Seagen Inc., among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store